Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597

Abstract

Purpose Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200